Chemotherapy using anthracyclines effectively treats cancer but can damage the heart, leading to cardiac dysfunction. New preclinical research indicates that remote ischaemic conditioning (RIC) may shield the heart during treatment without compromising chemotherapy's effectiveness against tumors.
Anthracyclines, like doxorubicin, are vital in treating various cancers. However, they are known to cause cardiotoxicity, resulting in long-term heart issues and reduced quality of life for survivors. Despite extensive research, preventative strategies have been limited.
RIC is a non-drug intervention involving brief periods of reduced blood flow and reperfusion applied to a limb. This controlled stress is believed to activate protective biological pathways that shield organs like the heart from injury.
In an experimental study, researchers used tumor-bearing mice to assess RIC's cardioprotective potential during chemotherapy. Mice received doxorubicin injections, with one group also undergoing weekly RIC. The RIC protocol involved cycles of hindlimb ischemia followed by reperfusion. Cardiac function was monitored via echocardiography, alongside tumor growth, survival, and body weight.
Doxorubicin treatment reduced survival, inhibited tumor growth, and caused cardiac injury. However, mice receiving RIC maintained significantly better cardiac function, preserving ejection fraction and mitigating structural heart changes.
Crucially, RIC did not appear to weaken the chemotherapy's anti-tumor effects. Tumor growth inhibition was similar between groups, suggesting cardioprotection occurred without reducing chemotherapy efficacy.
While these findings are from a preclinical model, they highlight RIC's potential as a simple, low-cost strategy to mitigate anthracycline-induced cardiotoxicity. Further clinical research is necessary to confirm its safety and efficacy in human patients.